EURTAC

NCT00446225 📎

Regimen

Experimental: erlotinib
Control: platinum doublet

Population

European advanced EGFR-mut NSCLC

Key finding

mPFS 9.7 vs 5.2 mo, HR 0.37 (0.25-0.54); erlotinib 1L confirmed in Caucasian EGFR-mut

Source: PMID 22285168

Timeline

Enrollment start: 2007-02-15 📎

Guideline citations

NCCN NSCLC Version 5.2026 (p.112)